Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.65 |
| ▸ | DUSP22 | Q9NRW4 | 3/20 | 0.65 |
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882923 | 1.00 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1882924 | 1.00 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1887625 | 0.90 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1110973 | 0.90 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1110972 | 0.90 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1192924 | 0.89 | CFTR (0.79) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1888007 | 0.89 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1888005 | 0.89 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1888004 | 0.89 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 | |
| SCHEMBL1885081 | 0.85 | CFTR (1.00) | CFTRMEN1KMT2ANLRP3DUSP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | claimed |
| EP-2866835-A1 | GPBP-1 INHIBITION AND ITS THERAPEUTIC USE | Fibrostatin, S.L. (ES) | 2015-05-06 | — | — | EP | claimed |
| WO-2014006020-A1 | GPBP-1 INHIBITION AND ITS THERAPEUTIC USE | FIBROSTATIN, S.L. (ES) | 2014-01-09 | — | — | WO | claimed |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | UNIVERSITAT DE VALENCIA (ES) | 2014-01-02 | — | — | US | claimed |
| WO-2009079373-A2 | INHIBITORS OF CALCIUM-ACTIVATED CHLORIDE CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | WO | claimed |
| US-7235573-B2 | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | claimed |
| EP-1549321-A4 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1549321-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | claimed |
| WO-2004028480-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040063695-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-04-01 | — | — | US | claimed |
| US-20250367207-A1 | OCULAR PHARMACEUTICAL COMPOSITIONS | UNIV CALIFORNIA (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250339383-A1 | FUNCTIONAL POROSOME MANIPULATION | POROSOME THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20240316152-A1 | FUNCTIONAL POROSOME MANIPULATION | POROSOME THERAPEUTICS INC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240156828-A1 | OCULAR PHARMACEUTICAL COMPOSITIONS | UNIV CALIFORNIA (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2004103371-A1 | USE OF CFTR INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED DIARRHEA | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| US-20040235879-A1 | Method for treatment of chemotherapy-induced diarrhea | PHARMACIA & UPJOHN COMPANY | 2004-11-25 | — | — | US | disclosed |
| WO-2004028480-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040063695-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367207-A1 | OCULAR PHARMACEUTICAL COMPOSITIONS | PLA2G2D, PLA2G2C, PLA2G3 | CFTR 94/4885MEN1 4166/4885KMT2A 4713/4885 |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | CFTR, TMEM205, TMEM33 | CFTR 1/4885MEN1 4413/4885KMT2A 4563/4885 |
| US-20240156828-A1 | OCULAR PHARMACEUTICAL COMPOSITIONS | PLA2G2D, PLA2G2C, PLA2G3 | CFTR 94/4885MEN1 4166/4885KMT2A 4713/4885 |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | CFTR 530/4885MEN1 4339/4885KMT2A 3885/4885 |
| US-20040063695-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | CFTR, TMEM205, TMEM33 | CFTR 1/4885MEN1 4413/4885KMT2A 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.